{"id":358270,"date":"2025-08-29T12:04:09","date_gmt":"2025-08-29T12:04:09","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-kiniksa-pharmaceuticals-international\/"},"modified":"2025-08-29T12:04:09","modified_gmt":"2025-08-29T12:04:09","slug":"how-to-buy-kiniksa-pharmaceuticals-international","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-kiniksa-pharmaceuticals-international\/","title":{"rendered":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Kiniksa Pharmaceuticals International, plc (KNSA) – \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Kiniksa Pharmaceuticals International, plc (KNSA)"},"content":{"rendered":"
text<\/div><\/div>","protected":false},"excerpt":{"rendered":"

text<\/p>\n","protected":false},"author":129,"featured_media":334054,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-358270","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"C\u00e1ch Mua C\u1ed5 Phi\u1ebfu Kiniksa Pharmaceuticals International, plc (KNSA) - \u0110\u1ea7u T\u01b0 V\u00e0o C\u1ed5 Phi\u1ebfu Kiniksa Pharmaceuticals International, plc (KNSA)","h1_source":{"label":"H1","type":"text","formatted_value":"C\u00e1ch Mua C\u1ed5 Phi\u1ebfu Kiniksa Pharmaceuticals International, plc (KNSA) - \u0110\u1ea7u T\u01b0 V\u00e0o C\u1ed5 Phi\u1ebfu Kiniksa Pharmaceuticals International, plc (KNSA)"},"description":"T\u00ecm hi\u1ec3u c\u00e1ch \u0111\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Kiniksa Pharmaceuticals (KNSA) v\u1edbi gi\u00e1 hi\u1ec7n t\u1ea1i $33,50, ti\u1ec1m n\u0103ng t\u0103ng tr\u01b0\u1edfng v\u00e0 quy tr\u00ecnh mua t\u1eebng b\u01b0\u1edbc cho c\u01a1 h\u1ed9i c\u00f4ng ngh\u1ec7 sinh h\u1ecdc tim m\u1ea1ch.","description_source":{"label":"Description","type":"textarea","formatted_value":"T\u00ecm hi\u1ec3u c\u00e1ch \u0111\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Kiniksa Pharmaceuticals (KNSA) v\u1edbi gi\u00e1 hi\u1ec7n t\u1ea1i $33,50, ti\u1ec1m n\u0103ng t\u0103ng tr\u01b0\u1edfng v\u00e0 quy tr\u00ecnh mua t\u1eebng b\u01b0\u1edbc cho c\u01a1 h\u1ed9i c\u00f4ng ngh\u1ec7 sinh h\u1ecdc tim m\u1ea1ch."},"intro":"B\u1ea1n \u0111ang ngh\u0129 \u0111\u1ebfn vi\u1ec7c \u0111\u1ea7u t\u01b0 v\u00e0o m\u1ed9t c\u00f4ng ty c\u00f4ng ngh\u1ec7 sinh h\u1ecdc \u0111ang t\u1ea1o d\u1ea5u \u1ea5n trong l\u0129nh v\u1ef1c y h\u1ecdc tim m\u1ea1ch? Kiniksa Pharmaceuticals (KNSA) k\u1ebft h\u1ee3p khoa h\u1ecdc ti\u00ean ti\u1ebfn v\u1edbi t\u0103ng tr\u01b0\u1edfng th\u01b0\u01a1ng m\u1ea1i \u1ea5n t\u01b0\u1ee3ng\u2014ho\u00e0n h\u1ea3o cho c\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 mu\u1ed1n ti\u1ebfp c\u1eadn l\u0129nh v\u1ef1c ch\u0103m s\u00f3c s\u1ee9c kh\u1ecfe \u0111\u1ed5i m\u1edbi. V\u1edbi thu\u1ed1c ch\u1ee7 l\u1ef1c ARCALYST \u0111ang thay \u0111\u1ed5i c\u00e1ch \u0111i\u1ec1u tr\u1ecb vi\u00eam m\u00e0ng ngo\u00e0i tim t\u00e1i ph\u00e1t, c\u00f4ng ty n\u00e0y \u0111\u1ea1i di\u1ec7n cho t\u01b0\u01a1ng lai c\u1ee7a li\u1ec7u ph\u00e1p tim m\u1ea1ch. H\u00e3y c\u00f9ng kh\u00e1m ph\u00e1 l\u00fd do t\u1ea1i sao KNSA x\u1ee9ng \u0111\u00e1ng \u0111\u01b0\u1ee3c b\u1ea1n quan t\u00e2m v\u00e0 c\u00e1ch b\u1ea1n c\u00f3 th\u1ec3 tr\u1edf th\u00e0nh m\u1ed9t ph\u1ea7n trong c\u00e2u chuy\u1ec7n t\u0103ng tr\u01b0\u1edfng c\u1ee7a h\u1ecd.","intro_source":{"label":"Intro","type":"text","formatted_value":"B\u1ea1n \u0111ang ngh\u0129 \u0111\u1ebfn vi\u1ec7c \u0111\u1ea7u t\u01b0 v\u00e0o m\u1ed9t c\u00f4ng ty c\u00f4ng ngh\u1ec7 sinh h\u1ecdc \u0111ang t\u1ea1o d\u1ea5u \u1ea5n trong l\u0129nh v\u1ef1c y h\u1ecdc tim m\u1ea1ch? Kiniksa Pharmaceuticals (KNSA) k\u1ebft h\u1ee3p khoa h\u1ecdc ti\u00ean ti\u1ebfn v\u1edbi t\u0103ng tr\u01b0\u1edfng th\u01b0\u01a1ng m\u1ea1i \u1ea5n t\u01b0\u1ee3ng\u2014ho\u00e0n h\u1ea3o cho c\u00e1c nh\u00e0 \u0111\u1ea7u t\u01b0 mu\u1ed1n ti\u1ebfp c\u1eadn l\u0129nh v\u1ef1c ch\u0103m s\u00f3c s\u1ee9c kh\u1ecfe \u0111\u1ed5i m\u1edbi. V\u1edbi thu\u1ed1c ch\u1ee7 l\u1ef1c ARCALYST \u0111ang thay \u0111\u1ed5i c\u00e1ch \u0111i\u1ec1u tr\u1ecb vi\u00eam m\u00e0ng ngo\u00e0i tim t\u00e1i ph\u00e1t, c\u00f4ng ty n\u00e0y \u0111\u1ea1i di\u1ec7n cho t\u01b0\u01a1ng lai c\u1ee7a li\u1ec7u ph\u00e1p tim m\u1ea1ch. H\u00e3y c\u00f9ng kh\u00e1m ph\u00e1 l\u00fd do t\u1ea1i sao KNSA x\u1ee9ng \u0111\u00e1ng \u0111\u01b0\u1ee3c b\u1ea1n quan t\u00e2m v\u00e0 c\u00e1ch b\u1ea1n c\u00f3 th\u1ec3 tr\u1edf th\u00e0nh m\u1ed9t ph\u1ea7n trong c\u00e2u chuy\u1ec7n t\u0103ng tr\u01b0\u1edfng c\u1ee7a h\u1ecd."},"body_html":"

\ud83d\udcc8 C\u1ed5 phi\u1ebfu Kiniksa: Gi\u00e1 Hi\u1ec7n T\u1ea1i v\u00e0 C\u00e1c Ng\u00e0y Quan Tr\u1ecdng<\/strong><\/p>

T\u00ednh \u0111\u1ebfn ng\u00e0y 29 th\u00e1ng 8 n\u0103m 2025, Kiniksa Pharmaceuticals (KNSA) giao d\u1ecbch \u1edf m\u1ee9c $33,50<\/strong> tr\u00ean NASDAQ. H\u00e3y \u0111\u00e1nh d\u1ea5u l\u1ecbch c\u1ee7a b\u1ea1n: ng\u00e0y 3 th\u00e1ng 11 n\u0103m 2025<\/strong> l\u00e0 ng\u00e0y c\u1ef1c k\u1ef3 quan tr\u1ecdng\u2014\u0111\u00f3 l\u00e0 khi c\u00f4ng ty c\u00f4ng b\u1ed1 b\u00e1o c\u00e1o thu nh\u1eadp qu\u00fd 3. L\u1ecbch s\u1eed cho th\u1ea5y c\u00e1c th\u00f4ng b\u00e1o h\u00e0ng qu\u00fd n\u00e0y th\u01b0\u1eddng l\u00e0m bi\u1ebfn \u0111\u1ed9ng \u0111\u00e1ng k\u1ec3 gi\u00e1 c\u1ed5 phi\u1ebfu.<\/p>

C\u00e1ch B\u00e1o C\u00e1o Thu Nh\u1eadp \u1ea2nh H\u01b0\u1edfng \u0110\u1ebfn C\u1ed5 Phi\u1ebfu KNSA<\/strong><\/p>
Ng\u00e0y<\/th>S\u1ef1 ki\u1ec7n<\/th>Gi\u00e1 Tr\u01b0\u1edbc Tin<\/th>Thay \u0110\u1ed5i Sau Tin<\/th><\/tr> <\/thead>
29 Th\u00e1ng 7, 2025<\/td>B\u00e1o c\u00e1o Qu\u00fd 2<\/td>$32,15<\/td>+4,2%<\/strong> (v\u01b0\u1ee3t d\u1ef1 b\u00e1o)<\/td><\/tr>
29 Th\u00e1ng 4, 2025<\/td>B\u00e1o c\u00e1o Qu\u00fd 1<\/td>$28,40<\/td>+8,1%<\/strong> (t\u0103ng d\u1ef1 b\u00e1o)<\/td><\/tr>
25 Th\u00e1ng 2, 2025<\/td>K\u1ebft qu\u1ea3 H\u00e0ng N\u0103m<\/td>$26,80<\/td>+6,3%<\/strong> (tri\u1ec3n v\u1ecdng m\u1ea1nh m\u1ebd)<\/td><\/tr>
4 Th\u00e1ng 11, 2024<\/td>B\u00e1o c\u00e1o Qu\u00fd 3<\/td>$24,50<\/td>-3,2%<\/strong> (k\u1ebft qu\u1ea3 h\u1ed7n h\u1ee3p)<\/td><\/tr>
1 Th\u00e1ng 8, 2024<\/td>B\u00e1o c\u00e1o Qu\u00fd 2<\/td>$22,75<\/td>+7,5%<\/strong> (l\u1ee3i nhu\u1eadn b\u1ea5t ng\u1edd)<\/td><\/tr>
2 Th\u00e1ng 5, 2024<\/td>B\u00e1o c\u00e1o Qu\u00fd 1<\/td>$20,10<\/td>+12,9%<\/strong> (t\u0103ng d\u1ef1 b\u00e1o)<\/td><\/tr> <\/tbody> <\/table>

Nh\u1eadn \u0110\u1ecbnh Xu H\u01b0\u1edbng<\/strong>: C\u00e1c b\u1ea5t ng\u1edd t\u00edch c\u1ef1c v\u1ec1 thu nh\u1eadp th\u01b0\u1eddng gi\u00fap KNSA t\u0103ng t\u1eeb 4-8% trong v\u00e0i ng\u00e0y. B\u00e1o c\u00e1o th\u00e1ng 7 n\u0103m 2025 cho th\u1ea5y s\u1ee9c m\u1ea1nh v\u01b0\u1ee3t tr\u1ed9i v\u1edbi doanh thu ARCALYST t\u0103ng 52% so v\u1edbi c\u00f9ng k\u1ef3 n\u0103m tr\u01b0\u1edbc l\u00ean 156,8 tri\u1ec7u USD, \u0111\u1ea9y c\u1ed5 phi\u1ebfu l\u00ean m\u1ee9c cao m\u1edbi.<\/p>

H\u00e0nh Tr\u00ecnh Gi\u00e1 6 Th\u00e1ng (Th\u00e1ng 3 - Th\u00e1ng 8 N\u0103m 2025)<\/strong><\/p>

C\u1ed5 phi\u1ebfu KNSA \u0111\u00e3 mang l\u1ea1i l\u1ee3i nhu\u1eadn \u1ea5n t\u01b0\u1ee3ng 38,2%<\/strong> trong giai \u0111o\u1ea1n n\u00e0y:<\/p>

  • Th\u00e1ng 3<\/strong>: $24,20 (sau giai \u0111o\u1ea1n c\u1ee7ng c\u1ed1 m\u00f9a \u0111\u00f4ng)<\/li>
  • Th\u00e1ng 4<\/strong>: $28,40 (b\u00e1o c\u00e1o qu\u00fd 1 v\u01b0\u1ee3t k\u1ef3 v\u1ecdng)<\/li>
  • Th\u00e1ng 6<\/strong>: $31,80 (d\u1ef1 \u0111o\u00e1n t\u0103ng d\u1ef1 b\u00e1o)<\/li>
  • Th\u00e1ng 7<\/strong>: $33,65 (b\u00f9ng n\u1ed5 b\u00e1o c\u00e1o qu\u00fd 2)<\/li>
  • Th\u00e1ng 8<\/strong>: $33,50 (c\u1ee7ng c\u1ed1 hi\u1ec7n t\u1ea1i)<\/li> <\/ul>

    T\u1ea1i sao gi\u00e1 ti\u1ebfp t\u1ee5c t\u0103ng?<\/strong><\/p>

    • \u0110\u01a1n thu\u1ed1c ARCALYST t\u0103ng l\u00ean h\u01a1n 3.475 b\u00e1c s\u0129<\/li>
    • Nhu c\u1ea7u thu\u1ed1c tim m\u1ea1ch t\u0103ng m\u1ea1nh sau \u0111\u1ea1i d\u1ecbch<\/li>
    • L\u1ee3i nhu\u1eadn chuy\u1ec3n sang d\u01b0\u01a1ng v\u1edbi thu nh\u1eadp r\u00f2ng qu\u00fd 2 \u0111\u1ea1t 17,8 tri\u1ec7u USD<\/li> <\/ul>

      \ud83d\udd2e D\u1ef1 B\u00e1o Gi\u00e1: 2025-2030<\/strong><\/p>

      • 2025 (Cu\u1ed1i n\u0103m)<\/strong>: $38-42 (t\u0103ng tr\u01b0\u1edfng ARCALYST ti\u1ebfp t\u1ee5c + ti\u1ebfn tri\u1ec3n trong pipeline) \u2192 MUA M\u1ea0NH<\/strong><\/li>
      • 2026<\/strong>: $45-52 (d\u1eef li\u1ec7u giai \u0111o\u1ea1n 2 KPL-387 + m\u1edf r\u1ed9ng th\u1ecb tr\u01b0\u1eddng)<\/li>
      • 2028<\/strong>: $65-80 (c\u00f3 th\u1ec3 ph\u00ea duy\u1ec7t thu\u1ed1c m\u1edbi + t\u0103ng tr\u01b0\u1edfng qu\u1ed1c t\u1ebf)<\/li>
      • 2030<\/strong>: $100+ (th\u1ed1ng l\u0129nh l\u0129nh v\u1ef1c tim m\u1ea1ch + tr\u01b0\u1edfng th\u00e0nh pipeline)<\/li> <\/ul>

        K\u1ebft lu\u1eadn<\/strong>: R\u1ea5t ph\u00f9 h\u1ee3p cho nh\u00e0 \u0111\u1ea7u t\u01b0 t\u0103ng tr\u01b0\u1edfng d\u00e0i h\u1ea1n. Nh\u00e0 giao d\u1ecbch ng\u1eafn h\u1ea1n n\u00ean theo d\u00f5i s\u00e1t b\u00e1o c\u00e1o thu nh\u1eadp th\u00e1ng 11.<\/p>

        \u26a0\ufe0f R\u1ee7i Ro Ch\u00ednh v\u00e0 T\u00edn Hi\u1ec7u T\u00edch C\u1ef1c<\/strong><\/p>

        R\u1ee7i ro c\u1ea7n l\u01b0u \u00fd<\/strong><\/p>

        • R\u00e0o c\u1ea3n FDA<\/strong>: B\u1ea5t k\u1ef3 s\u1ef1 ch\u1eadm tr\u1ec5 n\u00e0o trong ph\u00ea duy\u1ec7t KPL-387 c\u00f3 th\u1ec3 \u1ea3nh h\u01b0\u1edfng \u0111\u1ebfn d\u1ef1 b\u00e1o n\u0103m 2028<\/li>
        • Bi\u1ebfn \u0111\u1ed9ng c\u00f4ng ngh\u1ec7 sinh h\u1ecdc<\/strong>: Bi\u00ean \u0111\u1ed9 52 tu\u1ea7n t\u1eeb $17,82 \u0111\u1ebfn $34,55 cho th\u1ea5y ti\u1ec1m n\u0103ng dao \u0111\u1ed9ng 94%<\/li>
        • C\u1ea1nh tranh<\/strong>: C\u00e1c c\u00f4ng ty d\u01b0\u1ee3c l\u1edbn h\u01a1n \u0111ang ph\u00e1t tri\u1ec3n c\u00e1c ch\u1ea5t \u1ee9c ch\u1ebf IL-1 t\u01b0\u01a1ng t\u1ef1<\/li>
        • \u0110\u1ed9 \u1ed5n \u0111\u1ecbnh l\u1ee3i nhu\u1eadn<\/strong>: M\u1eb7c d\u00f9 c\u1ea3i thi\u1ec7n, thu nh\u1eadp v\u1eabn d\u1ec5 b\u1ecb \u1ea3nh h\u01b0\u1edfng b\u1edfi chi ph\u00ed R&D<\/li> <\/ul>

          T\u00edn hi\u1ec7u t\u00edch c\u1ef1c cho n\u0103m 2025<\/strong><\/p>

          • T\u0103ng tr\u01b0\u1edfng b\u00f9ng n\u1ed5<\/strong>: D\u1ef1 b\u00e1o doanh thu ARCALYST \u0111\u01b0\u1ee3c n\u00e2ng l\u00ean 625-640 tri\u1ec7u USD (t\u1eeb 590-605 tri\u1ec7u USD)<\/li>
          • Ti\u1ebfn tri\u1ec3n pipeline<\/strong>: KPL-387 b\u01b0\u1edbc v\u00e0o giai \u0111o\u1ea1n th\u1eed nghi\u1ec7m 2\/3 cho m\u1edf r\u1ed9ng tim m\u1ea1ch<\/li>
          • T\u1ef1 tin c\u1ee7a nh\u00e0 ph\u00e2n t\u00edch<\/strong>: 6 \u0111\u00e1nh gi\u00e1 \"Mua M\u1ea1nh\" v\u1edbi m\u1ee5c ti\u00eau trung b\u00ecnh $45,17 (t\u0103ng 35%)<\/li>
          • V\u1ecb th\u1ebf th\u1ecb tr\u01b0\u1eddng<\/strong>: Nh\u00e0 \u0111\u1ed5i m\u1edbi h\u00e0ng \u0111\u1ea7u trong \u0111i\u1ec1u tr\u1ecb vi\u00eam m\u00e0ng ngo\u00e0i tim t\u00e1i ph\u00e1t<\/li> <\/ul>

            \ud83d\udee1\ufe0f Ng\u01b0\u1eddi m\u1edbi n\u00ean l\u00e0m g\u00ec h\u00f4m nay?<\/strong><\/p>

            1. B\u1eaft \u0111\u1ea7u nh\u1ecf<\/strong>: Ph\u00e2n b\u1ed5 3-5% danh m\u1ee5c cho KNSA\u2014c\u00f4ng ngh\u1ec7 sinh h\u1ecdc \u0111\u00f2i h\u1ecfi qu\u1ea3n l\u00fd v\u1ecb th\u1ebf c\u1ea9n th\u1eadn<\/li>
            2. Trung b\u00ecnh gi\u00e1<\/strong>: Mua t\u1eebng ph\u1ea7n quanh c\u00e1c ng\u00e0y b\u00e1o c\u00e1o thu nh\u1eadp \u0111\u1ec3 gi\u1ea3m r\u1ee7i ro th\u1eddi \u0111i\u1ec3m<\/li>
            3. \u0110\u1eb7t l\u1ec7nh d\u1eebng l\u1ed7<\/strong>: B\u1ea3o v\u1ec7 kh\u1ecfi bi\u1ebfn \u0111\u1ed9ng c\u00f4ng ngh\u1ec7 sinh h\u1ecdc v\u1edbi m\u1ee9c gi\u1ea3m 15-20%<\/li>
            4. Theo d\u00f5i ng\u00e0y 3 th\u00e1ng 11<\/strong>: B\u00e1o c\u00e1o qu\u00fd 3 c\u00f3 th\u1ec3 l\u00e0 ch\u1ea5t x\u00fac t\u00e1c l\u1edbn ti\u1ebfp theo<\/li> <\/ol>

              Ch\u00e2m ng\u00f4n h\u00e0i h\u01b0\u1edbc cho nh\u00e0 giao d\u1ecbch<\/em>: \"Giao d\u1ecbch c\u1ed5 phi\u1ebfu c\u00f4ng ngh\u1ec7 sinh h\u1ecdc nh\u01b0 KNSA gi\u1ed1ng nh\u01b0 h\u1eb9n h\u00f2\u2014\u0111\u00f4i khi b\u1ea1n c\u00f3 k\u1ebft th\u00fac c\u1ed5 t\u00edch, \u0111\u00f4i khi b\u1ecb FDA 'b\u1ecf r\u01a1i'. Lu\u00f4n c\u00f3 chi\u1ebfn l\u01b0\u1ee3c tho\u00e1t!\"<\/p>

              \u2705 C\u00e1ch Mua C\u1ed5 Phi\u1ebfu Kiniksa Pharmaceuticals International, plc (KNSA) - T\u1eebng B\u01b0\u1edbc<\/strong><\/p>
              B\u01b0\u1edbc<\/th>H\u00e0nh \u0110\u1ed9ng<\/th>T\u1ea1i Sao Quan Tr\u1ecdng<\/th><\/tr> <\/thead>
              1<\/td>Ch\u1ecdn n\u1ec1n t\u1ea3ng giao d\u1ecbch<\/td>\u0110\u1ea3m b\u1ea3o c\u00f3 truy c\u1eadp NASDAQ v\u00e0 ph\u00ed h\u1ee3p l\u00fd<\/td><\/tr>
              2<\/td>Ho\u00e0n t\u1ea5t x\u00e1c minh t\u00e0i kho\u1ea3n<\/td>Th\u01b0\u1eddng y\u00eau c\u1ea7u ID v\u00e0 b\u1eb1ng ch\u1ee9ng \u0111\u1ecba ch\u1ec9<\/td><\/tr>
              3<\/td>N\u1ea1p ti\u1ec1n<\/td>B\u1eaft \u0111\u1ea7u v\u1edbi s\u1ed1 ti\u1ec1n b\u1ea1n c\u1ea3m th\u1ea5y tho\u1ea3i m\u00e1i khi r\u1ee7i ro<\/td><\/tr>
              4<\/td>T\u00ecm ki\u1ebfm \"KNSA\"<\/td>S\u1eed d\u1ee5ng m\u00e3 ch\u1ee9ng kho\u00e1n, kh\u00f4ng ch\u1ec9 t\u00ean c\u00f4ng ty<\/td><\/tr>
              5<\/td>Ch\u1ecdn lo\u1ea1i l\u1ec7nh<\/td>L\u1ec7nh gi\u1edbi h\u1ea1n gi\u00fap tr\u00e1nh tr\u1ea3 gi\u00e1 cao trong bi\u1ebfn \u0111\u1ed9ng<\/td><\/tr>
              6<\/td>Xem l\u1ea1i v\u00e0 x\u00e1c nh\u1eadn<\/td>Ki\u1ec3m tra t\u1ef7 l\u1ec7 hoa h\u1ed3ng\u2014nh\u1eafm d\u01b0\u1edbi 1% chi ph\u00ed giao d\u1ecbch<\/td><\/tr>
              7<\/td>Gi\u00e1m s\u00e1t v\u1ecb th\u1ebf<\/td>\u0110\u1eb7t c\u1ea3nh b\u00e1o gi\u00e1 cho c\u00e1c ng\u00e0y b\u00e1o c\u00e1o v\u00e0 m\u1ee9c quan tr\u1ecdng<\/td><\/tr> <\/tbody> <\/table>

              \ud83d\udca1 T\u1ea1i sao Pocket Option ph\u00f9 h\u1ee3p v\u1edbi nh\u00e0 \u0111\u1ea7u t\u01b0 m\u1edbi<\/strong><\/p>

              Pocket Option cung c\u1ea5p kh\u1ea3 n\u0103ng ti\u1ebfp c\u1eadn xu\u1ea5t s\u1eafc cho \u0111\u1ea7u t\u01b0 c\u00f4ng ngh\u1ec7 sinh h\u1ecdc:<\/p>

              • S\u1ed1 ti\u1ec1n n\u1ea1p t\u1ed1i thi\u1ec3u<\/strong>: Ch\u1ec9 $5 cho ph\u00e9p b\u1ea1n th\u1eed chi\u1ebfn l\u01b0\u1ee3c v\u1edbi r\u1ee7i ro th\u1ea5p<\/li>
              • X\u00e1c minh nhanh<\/strong>: KYC ho\u00e0n th\u00e0nh trong v\u00e0i ph\u00fat v\u1edbi m\u1ed9t t\u00e0i li\u1ec7u duy nh\u1ea5t<\/li>
              • R\u00fat ti\u1ec1n \u0111a d\u1ea1ng<\/strong>: H\u01a1n 100 ph\u01b0\u01a1ng th\u1ee9c bao g\u1ed3m ti\u1ec1n \u0111i\u1ec7n t\u1eed, v\u00ed \u0111i\u1ec7n t\u1eed v\u00e0 chuy\u1ec3n kho\u1ea3n ng\u00e2n h\u00e0ng<\/li>
              • N\u1ec1n t\u1ea3ng th\u00e2n thi\u1ec7n ng\u01b0\u1eddi d\u00f9ng<\/strong>: Ho\u00e0n h\u1ea3o cho ng\u01b0\u1eddi m\u1edbi l\u00e0m quen v\u1edbi c\u1ed5 phi\u1ebfu c\u00f4ng ngh\u1ec7 sinh h\u1ecdc ph\u1ee9c t\u1ea1p<\/li> <\/ul>

                \ud83c\udf0d Kiniksa n\u0103m 2025: Nh\u00e0 L\u00e3nh \u0110\u1ea1o \u0110\u1ed5i M\u1edbi Tim M\u1ea1ch<\/strong><\/p>

                Kiniksa Pharmaceuticals th\u1ed1ng l\u0129nh th\u1ecb tr\u01b0\u1eddng vi\u00eam m\u00e0ng ngo\u00e0i tim t\u00e1i ph\u00e1t v\u1edbi ARCALYST, \u0111i\u1ec1u tr\u1ecb m\u1ed9t b\u1ec7nh vi\u00eam tim nghi\u00eam tr\u1ecdng \u1ea3nh h\u01b0\u1edfng \u0111\u1ebfn h\u00e0ng ng\u00e0n ng\u01b0\u1eddi tr\u00ean to\u00e0n c\u1ea7u. Ngo\u00e0i th\u00e0nh c\u00f4ng th\u01b0\u01a1ng m\u1ea1i, h\u1ecd \u0111ang ph\u00e1t tri\u1ec3n KPL-387\u2014m\u1ed9t kh\u00e1ng th\u1ec3 \u0111\u01a1n d\u00f2ng th\u1ebf h\u1ec7 m\u1edbi c\u00f3 th\u1ec3 c\u00e1ch m\u1ea1ng h\u00f3a \u0111i\u1ec1u tr\u1ecb vi\u00eam tim m\u1ea1ch.<\/p>

                S\u1ef1 th\u1eadt th\u00fa v\u1ecb n\u0103m 2025<\/strong>: Nh\u00f3m nghi\u00ean c\u1ee9u c\u1ee7a Kiniksa ph\u00e1t hi\u1ec7n c\u00f4ng ngh\u1ec7 \u1ee9c ch\u1ebf IL-1 c\u1ee7a h\u1ecd c\u0169ng c\u00f3 th\u1ec3 gi\u00fap \u0111i\u1ec1u tr\u1ecb c\u00e1c bi\u1ebfn ch\u1ee9ng tim m\u1ea1ch do COVID k\u00e9o d\u00e0i, m\u1edf ra c\u01a1 h\u1ed9i th\u1ecb tr\u01b0\u1eddng kh\u1ed5ng l\u1ed3 tr\u1ecb gi\u00e1 h\u00e0ng t\u1ef7 \u0111\u00f4 la!<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"

                \ud83d\udcc8 C\u1ed5 phi\u1ebfu Kiniksa: Gi\u00e1 Hi\u1ec7n T\u1ea1i v\u00e0 C\u00e1c Ng\u00e0y Quan Tr\u1ecdng<\/strong><\/p>\n

                T\u00ednh \u0111\u1ebfn ng\u00e0y 29 th\u00e1ng 8 n\u0103m 2025, Kiniksa Pharmaceuticals (KNSA) giao d\u1ecbch \u1edf m\u1ee9c $33,50<\/strong> tr\u00ean NASDAQ. H\u00e3y \u0111\u00e1nh d\u1ea5u l\u1ecbch c\u1ee7a b\u1ea1n: ng\u00e0y 3 th\u00e1ng 11 n\u0103m 2025<\/strong> l\u00e0 ng\u00e0y c\u1ef1c k\u1ef3 quan tr\u1ecdng\u2014\u0111\u00f3 l\u00e0 khi c\u00f4ng ty c\u00f4ng b\u1ed1 b\u00e1o c\u00e1o thu nh\u1eadp qu\u00fd 3. L\u1ecbch s\u1eed cho th\u1ea5y c\u00e1c th\u00f4ng b\u00e1o h\u00e0ng qu\u00fd n\u00e0y th\u01b0\u1eddng l\u00e0m bi\u1ebfn \u0111\u1ed9ng \u0111\u00e1ng k\u1ec3 gi\u00e1 c\u1ed5 phi\u1ebfu.<\/p>\n

                C\u00e1ch B\u00e1o C\u00e1o Thu Nh\u1eadp \u1ea2nh H\u01b0\u1edfng \u0110\u1ebfn C\u1ed5 Phi\u1ebfu KNSA<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n
                Ng\u00e0y<\/th>\nS\u1ef1 ki\u1ec7n<\/th>\nGi\u00e1 Tr\u01b0\u1edbc Tin<\/th>\nThay \u0110\u1ed5i Sau Tin<\/th>\n<\/tr>\n<\/thead>\n
                29 Th\u00e1ng 7, 2025<\/td>\nB\u00e1o c\u00e1o Qu\u00fd 2<\/td>\n$32,15<\/td>\n+4,2%<\/strong> (v\u01b0\u1ee3t d\u1ef1 b\u00e1o)<\/td>\n<\/tr>\n
                29 Th\u00e1ng 4, 2025<\/td>\nB\u00e1o c\u00e1o Qu\u00fd 1<\/td>\n$28,40<\/td>\n+8,1%<\/strong> (t\u0103ng d\u1ef1 b\u00e1o)<\/td>\n<\/tr>\n
                25 Th\u00e1ng 2, 2025<\/td>\nK\u1ebft qu\u1ea3 H\u00e0ng N\u0103m<\/td>\n$26,80<\/td>\n+6,3%<\/strong> (tri\u1ec3n v\u1ecdng m\u1ea1nh m\u1ebd)<\/td>\n<\/tr>\n
                4 Th\u00e1ng 11, 2024<\/td>\nB\u00e1o c\u00e1o Qu\u00fd 3<\/td>\n$24,50<\/td>\n-3,2%<\/strong> (k\u1ebft qu\u1ea3 h\u1ed7n h\u1ee3p)<\/td>\n<\/tr>\n
                1 Th\u00e1ng 8, 2024<\/td>\nB\u00e1o c\u00e1o Qu\u00fd 2<\/td>\n$22,75<\/td>\n+7,5%<\/strong> (l\u1ee3i nhu\u1eadn b\u1ea5t ng\u1edd)<\/td>\n<\/tr>\n
                2 Th\u00e1ng 5, 2024<\/td>\nB\u00e1o c\u00e1o Qu\u00fd 1<\/td>\n$20,10<\/td>\n+12,9%<\/strong> (t\u0103ng d\u1ef1 b\u00e1o)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

                Nh\u1eadn \u0110\u1ecbnh Xu H\u01b0\u1edbng<\/strong>: C\u00e1c b\u1ea5t ng\u1edd t\u00edch c\u1ef1c v\u1ec1 thu nh\u1eadp th\u01b0\u1eddng gi\u00fap KNSA t\u0103ng t\u1eeb 4-8% trong v\u00e0i ng\u00e0y. B\u00e1o c\u00e1o th\u00e1ng 7 n\u0103m 2025 cho th\u1ea5y s\u1ee9c m\u1ea1nh v\u01b0\u1ee3t tr\u1ed9i v\u1edbi doanh thu ARCALYST t\u0103ng 52% so v\u1edbi c\u00f9ng k\u1ef3 n\u0103m tr\u01b0\u1edbc l\u00ean 156,8 tri\u1ec7u USD, \u0111\u1ea9y c\u1ed5 phi\u1ebfu l\u00ean m\u1ee9c cao m\u1edbi.<\/p>\n

                H\u00e0nh Tr\u00ecnh Gi\u00e1 6 Th\u00e1ng (Th\u00e1ng 3 – Th\u00e1ng 8 N\u0103m 2025)<\/strong><\/p>\n

                C\u1ed5 phi\u1ebfu KNSA \u0111\u00e3 mang l\u1ea1i l\u1ee3i nhu\u1eadn \u1ea5n t\u01b0\u1ee3ng 38,2%<\/strong> trong giai \u0111o\u1ea1n n\u00e0y:<\/p>\n

                  \n
                • Th\u00e1ng 3<\/strong>: $24,20 (sau giai \u0111o\u1ea1n c\u1ee7ng c\u1ed1 m\u00f9a \u0111\u00f4ng)<\/li>\n
                • Th\u00e1ng 4<\/strong>: $28,40 (b\u00e1o c\u00e1o qu\u00fd 1 v\u01b0\u1ee3t k\u1ef3 v\u1ecdng)<\/li>\n
                • Th\u00e1ng 6<\/strong>: $31,80 (d\u1ef1 \u0111o\u00e1n t\u0103ng d\u1ef1 b\u00e1o)<\/li>\n
                • Th\u00e1ng 7<\/strong>: $33,65 (b\u00f9ng n\u1ed5 b\u00e1o c\u00e1o qu\u00fd 2)<\/li>\n
                • Th\u00e1ng 8<\/strong>: $33,50 (c\u1ee7ng c\u1ed1 hi\u1ec7n t\u1ea1i)<\/li>\n<\/ul>\n

                  T\u1ea1i sao gi\u00e1 ti\u1ebfp t\u1ee5c t\u0103ng?<\/strong><\/p>\n

                    \n
                  • \u0110\u01a1n thu\u1ed1c ARCALYST t\u0103ng l\u00ean h\u01a1n 3.475 b\u00e1c s\u0129<\/li>\n
                  • Nhu c\u1ea7u thu\u1ed1c tim m\u1ea1ch t\u0103ng m\u1ea1nh sau \u0111\u1ea1i d\u1ecbch<\/li>\n
                  • L\u1ee3i nhu\u1eadn chuy\u1ec3n sang d\u01b0\u01a1ng v\u1edbi thu nh\u1eadp r\u00f2ng qu\u00fd 2 \u0111\u1ea1t 17,8 tri\u1ec7u USD<\/li>\n<\/ul>\n

                    \ud83d\udd2e D\u1ef1 B\u00e1o Gi\u00e1: 2025-2030<\/strong><\/p>\n

                      \n
                    • 2025 (Cu\u1ed1i n\u0103m)<\/strong>: $38-42 (t\u0103ng tr\u01b0\u1edfng ARCALYST ti\u1ebfp t\u1ee5c + ti\u1ebfn tri\u1ec3n trong pipeline) \u2192 MUA M\u1ea0NH<\/strong><\/li>\n
                    • 2026<\/strong>: $45-52 (d\u1eef li\u1ec7u giai \u0111o\u1ea1n 2 KPL-387 + m\u1edf r\u1ed9ng th\u1ecb tr\u01b0\u1eddng)<\/li>\n
                    • 2028<\/strong>: $65-80 (c\u00f3 th\u1ec3 ph\u00ea duy\u1ec7t thu\u1ed1c m\u1edbi + t\u0103ng tr\u01b0\u1edfng qu\u1ed1c t\u1ebf)<\/li>\n
                    • 2030<\/strong>: $100+ (th\u1ed1ng l\u0129nh l\u0129nh v\u1ef1c tim m\u1ea1ch + tr\u01b0\u1edfng th\u00e0nh pipeline)<\/li>\n<\/ul>\n

                      K\u1ebft lu\u1eadn<\/strong>: R\u1ea5t ph\u00f9 h\u1ee3p cho nh\u00e0 \u0111\u1ea7u t\u01b0 t\u0103ng tr\u01b0\u1edfng d\u00e0i h\u1ea1n. Nh\u00e0 giao d\u1ecbch ng\u1eafn h\u1ea1n n\u00ean theo d\u00f5i s\u00e1t b\u00e1o c\u00e1o thu nh\u1eadp th\u00e1ng 11.<\/p>\n

                      \u26a0\ufe0f R\u1ee7i Ro Ch\u00ednh v\u00e0 T\u00edn Hi\u1ec7u T\u00edch C\u1ef1c<\/strong><\/p>\n

                      R\u1ee7i ro c\u1ea7n l\u01b0u \u00fd<\/strong><\/p>\n

                        \n
                      • R\u00e0o c\u1ea3n FDA<\/strong>: B\u1ea5t k\u1ef3 s\u1ef1 ch\u1eadm tr\u1ec5 n\u00e0o trong ph\u00ea duy\u1ec7t KPL-387 c\u00f3 th\u1ec3 \u1ea3nh h\u01b0\u1edfng \u0111\u1ebfn d\u1ef1 b\u00e1o n\u0103m 2028<\/li>\n
                      • Bi\u1ebfn \u0111\u1ed9ng c\u00f4ng ngh\u1ec7 sinh h\u1ecdc<\/strong>: Bi\u00ean \u0111\u1ed9 52 tu\u1ea7n t\u1eeb $17,82 \u0111\u1ebfn $34,55 cho th\u1ea5y ti\u1ec1m n\u0103ng dao \u0111\u1ed9ng 94%<\/li>\n
                      • C\u1ea1nh tranh<\/strong>: C\u00e1c c\u00f4ng ty d\u01b0\u1ee3c l\u1edbn h\u01a1n \u0111ang ph\u00e1t tri\u1ec3n c\u00e1c ch\u1ea5t \u1ee9c ch\u1ebf IL-1 t\u01b0\u01a1ng t\u1ef1<\/li>\n
                      • \u0110\u1ed9 \u1ed5n \u0111\u1ecbnh l\u1ee3i nhu\u1eadn<\/strong>: M\u1eb7c d\u00f9 c\u1ea3i thi\u1ec7n, thu nh\u1eadp v\u1eabn d\u1ec5 b\u1ecb \u1ea3nh h\u01b0\u1edfng b\u1edfi chi ph\u00ed R&D<\/li>\n<\/ul>\n

                        T\u00edn hi\u1ec7u t\u00edch c\u1ef1c cho n\u0103m 2025<\/strong><\/p>\n

                          \n
                        • T\u0103ng tr\u01b0\u1edfng b\u00f9ng n\u1ed5<\/strong>: D\u1ef1 b\u00e1o doanh thu ARCALYST \u0111\u01b0\u1ee3c n\u00e2ng l\u00ean 625-640 tri\u1ec7u USD (t\u1eeb 590-605 tri\u1ec7u USD)<\/li>\n
                        • Ti\u1ebfn tri\u1ec3n pipeline<\/strong>: KPL-387 b\u01b0\u1edbc v\u00e0o giai \u0111o\u1ea1n th\u1eed nghi\u1ec7m 2\/3 cho m\u1edf r\u1ed9ng tim m\u1ea1ch<\/li>\n
                        • T\u1ef1 tin c\u1ee7a nh\u00e0 ph\u00e2n t\u00edch<\/strong>: 6 \u0111\u00e1nh gi\u00e1 “Mua M\u1ea1nh” v\u1edbi m\u1ee5c ti\u00eau trung b\u00ecnh $45,17 (t\u0103ng 35%)<\/li>\n
                        • V\u1ecb th\u1ebf th\u1ecb tr\u01b0\u1eddng<\/strong>: Nh\u00e0 \u0111\u1ed5i m\u1edbi h\u00e0ng \u0111\u1ea7u trong \u0111i\u1ec1u tr\u1ecb vi\u00eam m\u00e0ng ngo\u00e0i tim t\u00e1i ph\u00e1t<\/li>\n<\/ul>\n

                          \ud83d\udee1\ufe0f Ng\u01b0\u1eddi m\u1edbi n\u00ean l\u00e0m g\u00ec h\u00f4m nay?<\/strong><\/p>\n

                            \n
                          1. B\u1eaft \u0111\u1ea7u nh\u1ecf<\/strong>: Ph\u00e2n b\u1ed5 3-5% danh m\u1ee5c cho KNSA\u2014c\u00f4ng ngh\u1ec7 sinh h\u1ecdc \u0111\u00f2i h\u1ecfi qu\u1ea3n l\u00fd v\u1ecb th\u1ebf c\u1ea9n th\u1eadn<\/li>\n
                          2. Trung b\u00ecnh gi\u00e1<\/strong>: Mua t\u1eebng ph\u1ea7n quanh c\u00e1c ng\u00e0y b\u00e1o c\u00e1o thu nh\u1eadp \u0111\u1ec3 gi\u1ea3m r\u1ee7i ro th\u1eddi \u0111i\u1ec3m<\/li>\n
                          3. \u0110\u1eb7t l\u1ec7nh d\u1eebng l\u1ed7<\/strong>: B\u1ea3o v\u1ec7 kh\u1ecfi bi\u1ebfn \u0111\u1ed9ng c\u00f4ng ngh\u1ec7 sinh h\u1ecdc v\u1edbi m\u1ee9c gi\u1ea3m 15-20%<\/li>\n
                          4. Theo d\u00f5i ng\u00e0y 3 th\u00e1ng 11<\/strong>: B\u00e1o c\u00e1o qu\u00fd 3 c\u00f3 th\u1ec3 l\u00e0 ch\u1ea5t x\u00fac t\u00e1c l\u1edbn ti\u1ebfp theo<\/li>\n<\/ol>\n

                            Ch\u00e2m ng\u00f4n h\u00e0i h\u01b0\u1edbc cho nh\u00e0 giao d\u1ecbch<\/em>: “Giao d\u1ecbch c\u1ed5 phi\u1ebfu c\u00f4ng ngh\u1ec7 sinh h\u1ecdc nh\u01b0 KNSA gi\u1ed1ng nh\u01b0 h\u1eb9n h\u00f2\u2014\u0111\u00f4i khi b\u1ea1n c\u00f3 k\u1ebft th\u00fac c\u1ed5 t\u00edch, \u0111\u00f4i khi b\u1ecb FDA ‘b\u1ecf r\u01a1i’. Lu\u00f4n c\u00f3 chi\u1ebfn l\u01b0\u1ee3c tho\u00e1t!”<\/p>\n

                            \u2705 C\u00e1ch Mua C\u1ed5 Phi\u1ebfu Kiniksa Pharmaceuticals International, plc (KNSA) – T\u1eebng B\u01b0\u1edbc<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n
                            B\u01b0\u1edbc<\/th>\nH\u00e0nh \u0110\u1ed9ng<\/th>\nT\u1ea1i Sao Quan Tr\u1ecdng<\/th>\n<\/tr>\n<\/thead>\n
                            1<\/td>\nCh\u1ecdn n\u1ec1n t\u1ea3ng giao d\u1ecbch<\/td>\n\u0110\u1ea3m b\u1ea3o c\u00f3 truy c\u1eadp NASDAQ v\u00e0 ph\u00ed h\u1ee3p l\u00fd<\/td>\n<\/tr>\n
                            2<\/td>\nHo\u00e0n t\u1ea5t x\u00e1c minh t\u00e0i kho\u1ea3n<\/td>\nTh\u01b0\u1eddng y\u00eau c\u1ea7u ID v\u00e0 b\u1eb1ng ch\u1ee9ng \u0111\u1ecba ch\u1ec9<\/td>\n<\/tr>\n
                            3<\/td>\nN\u1ea1p ti\u1ec1n<\/td>\nB\u1eaft \u0111\u1ea7u v\u1edbi s\u1ed1 ti\u1ec1n b\u1ea1n c\u1ea3m th\u1ea5y tho\u1ea3i m\u00e1i khi r\u1ee7i ro<\/td>\n<\/tr>\n
                            4<\/td>\nT\u00ecm ki\u1ebfm “KNSA”<\/td>\nS\u1eed d\u1ee5ng m\u00e3 ch\u1ee9ng kho\u00e1n, kh\u00f4ng ch\u1ec9 t\u00ean c\u00f4ng ty<\/td>\n<\/tr>\n
                            5<\/td>\nCh\u1ecdn lo\u1ea1i l\u1ec7nh<\/td>\nL\u1ec7nh gi\u1edbi h\u1ea1n gi\u00fap tr\u00e1nh tr\u1ea3 gi\u00e1 cao trong bi\u1ebfn \u0111\u1ed9ng<\/td>\n<\/tr>\n
                            6<\/td>\nXem l\u1ea1i v\u00e0 x\u00e1c nh\u1eadn<\/td>\nKi\u1ec3m tra t\u1ef7 l\u1ec7 hoa h\u1ed3ng\u2014nh\u1eafm d\u01b0\u1edbi 1% chi ph\u00ed giao d\u1ecbch<\/td>\n<\/tr>\n
                            7<\/td>\nGi\u00e1m s\u00e1t v\u1ecb th\u1ebf<\/td>\n\u0110\u1eb7t c\u1ea3nh b\u00e1o gi\u00e1 cho c\u00e1c ng\u00e0y b\u00e1o c\u00e1o v\u00e0 m\u1ee9c quan tr\u1ecdng<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

                            \ud83d\udca1 T\u1ea1i sao Pocket Option ph\u00f9 h\u1ee3p v\u1edbi nh\u00e0 \u0111\u1ea7u t\u01b0 m\u1edbi<\/strong><\/p>\n

                            Pocket Option cung c\u1ea5p kh\u1ea3 n\u0103ng ti\u1ebfp c\u1eadn xu\u1ea5t s\u1eafc cho \u0111\u1ea7u t\u01b0 c\u00f4ng ngh\u1ec7 sinh h\u1ecdc:<\/p>\n

                              \n
                            • S\u1ed1 ti\u1ec1n n\u1ea1p t\u1ed1i thi\u1ec3u<\/strong>: Ch\u1ec9 $5 cho ph\u00e9p b\u1ea1n th\u1eed chi\u1ebfn l\u01b0\u1ee3c v\u1edbi r\u1ee7i ro th\u1ea5p<\/li>\n
                            • X\u00e1c minh nhanh<\/strong>: KYC ho\u00e0n th\u00e0nh trong v\u00e0i ph\u00fat v\u1edbi m\u1ed9t t\u00e0i li\u1ec7u duy nh\u1ea5t<\/li>\n
                            • R\u00fat ti\u1ec1n \u0111a d\u1ea1ng<\/strong>: H\u01a1n 100 ph\u01b0\u01a1ng th\u1ee9c bao g\u1ed3m ti\u1ec1n \u0111i\u1ec7n t\u1eed, v\u00ed \u0111i\u1ec7n t\u1eed v\u00e0 chuy\u1ec3n kho\u1ea3n ng\u00e2n h\u00e0ng<\/li>\n
                            • N\u1ec1n t\u1ea3ng th\u00e2n thi\u1ec7n ng\u01b0\u1eddi d\u00f9ng<\/strong>: Ho\u00e0n h\u1ea3o cho ng\u01b0\u1eddi m\u1edbi l\u00e0m quen v\u1edbi c\u1ed5 phi\u1ebfu c\u00f4ng ngh\u1ec7 sinh h\u1ecdc ph\u1ee9c t\u1ea1p<\/li>\n<\/ul>\n

                              \ud83c\udf0d Kiniksa n\u0103m 2025: Nh\u00e0 L\u00e3nh \u0110\u1ea1o \u0110\u1ed5i M\u1edbi Tim M\u1ea1ch<\/strong><\/p>\n

                              Kiniksa Pharmaceuticals th\u1ed1ng l\u0129nh th\u1ecb tr\u01b0\u1eddng vi\u00eam m\u00e0ng ngo\u00e0i tim t\u00e1i ph\u00e1t v\u1edbi ARCALYST, \u0111i\u1ec1u tr\u1ecb m\u1ed9t b\u1ec7nh vi\u00eam tim nghi\u00eam tr\u1ecdng \u1ea3nh h\u01b0\u1edfng \u0111\u1ebfn h\u00e0ng ng\u00e0n ng\u01b0\u1eddi tr\u00ean to\u00e0n c\u1ea7u. Ngo\u00e0i th\u00e0nh c\u00f4ng th\u01b0\u01a1ng m\u1ea1i, h\u1ecd \u0111ang ph\u00e1t tri\u1ec3n KPL-387\u2014m\u1ed9t kh\u00e1ng th\u1ec3 \u0111\u01a1n d\u00f2ng th\u1ebf h\u1ec7 m\u1edbi c\u00f3 th\u1ec3 c\u00e1ch m\u1ea1ng h\u00f3a \u0111i\u1ec1u tr\u1ecb vi\u00eam tim m\u1ea1ch.<\/p>\n

                              S\u1ef1 th\u1eadt th\u00fa v\u1ecb n\u0103m 2025<\/strong>: Nh\u00f3m nghi\u00ean c\u1ee9u c\u1ee7a Kiniksa ph\u00e1t hi\u1ec7n c\u00f4ng ngh\u1ec7 \u1ee9c ch\u1ebf IL-1 c\u1ee7a h\u1ecd c\u0169ng c\u00f3 th\u1ec3 gi\u00fap \u0111i\u1ec1u tr\u1ecb c\u00e1c bi\u1ebfn ch\u1ee9ng tim m\u1ea1ch do COVID k\u00e9o d\u00e0i, m\u1edf ra c\u01a1 h\u1ed9i th\u1ecb tr\u01b0\u1eddng kh\u1ed5ng l\u1ed3 tr\u1ecb gi\u00e1 h\u00e0ng t\u1ef7 \u0111\u00f4 la!<\/p>\n"},"faq":[{"question":"L\u00e0m th\u1ebf n\u00e0o \u0111\u1ec3 b\u1eaft \u0111\u1ea7u \u0111\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Kiniksa Pharmaceuticals (KNSA)?","answer":"B\u1ea1n n\u00ean ch\u1ecdn m\u1ed9t n\u1ec1n t\u1ea3ng giao d\u1ecbch c\u00f3 truy c\u1eadp NASDAQ, ho\u00e0n t\u1ea5t x\u00e1c minh t\u00e0i kho\u1ea3n, n\u1ea1p ti\u1ec1n, t\u00ecm m\u00e3 c\u1ed5 phi\u1ebfu KNSA, ch\u1ecdn lo\u1ea1i l\u1ec7nh ph\u00f9 h\u1ee3p v\u00e0 theo d\u00f5i v\u1ecb th\u1ebf c\u1ee7a m\u00ecnh, \u0111\u1eb7c bi\u1ec7t l\u00e0 c\u00e1c ng\u00e0y c\u00f4ng b\u1ed1 b\u00e1o c\u00e1o thu nh\u1eadp."},{"question":"Gi\u00e1 c\u1ed5 phi\u1ebfu KNSA hi\u1ec7n t\u1ea1i l\u00e0 bao nhi\u00eau?","answer":"T\u00ednh \u0111\u1ebfn ng\u00e0y 29 th\u00e1ng 8 n\u0103m 2025, gi\u00e1 c\u1ed5 phi\u1ebfu KNSA l\u00e0 $33,50 tr\u00ean s\u00e0n NASDAQ."},{"question":"Nh\u1eefng r\u1ee7i ro ch\u00ednh khi \u0111\u1ea7u t\u01b0 v\u00e0o Kiniksa l\u00e0 g\u00ec?","answer":"C\u00e1c r\u1ee7i ro bao g\u1ed3m r\u00e0o c\u1ea3n ph\u00ea duy\u1ec7t c\u1ee7a FDA, bi\u1ebfn \u0111\u1ed9ng cao trong ng\u00e0nh c\u00f4ng ngh\u1ec7 sinh h\u1ecdc, c\u1ea1nh tranh t\u1eeb c\u00e1c c\u00f4ng ty d\u01b0\u1ee3c l\u1edbn v\u00e0 s\u1ef1 kh\u00f4ng \u1ed5n \u0111\u1ecbnh trong l\u1ee3i nhu\u1eadn do chi ph\u00ed nghi\u00ean c\u1ee9u v\u00e0 ph\u00e1t tri\u1ec3n."},{"question":"D\u1ef1 b\u00e1o gi\u00e1 c\u1ed5 phi\u1ebfu KNSA trong t\u01b0\u01a1ng lai nh\u01b0 th\u1ebf n\u00e0o?","answer":"D\u1ef1 b\u00e1o gi\u00e1 \u0111\u1ebfn n\u0103m 2030 c\u00f3 th\u1ec3 \u0111\u1ea1t tr\u00ean $100 nh\u1edd s\u1ef1 t\u0103ng tr\u01b0\u1edfng c\u1ee7a ARCALYST, ti\u1ebfn tri\u1ec3n trong pipeline v\u00e0 m\u1edf r\u1ed9ng th\u1ecb tr\u01b0\u1eddng qu\u1ed1c t\u1ebf."},{"question":"T\u1ea1i sao n\u00ean s\u1eed d\u1ee5ng Pocket Option \u0111\u1ec3 \u0111\u1ea7u t\u01b0 v\u00e0o KNSA?","answer":"Pocket Option c\u00f3 s\u1ed1 ti\u1ec1n n\u1ea1p t\u1ed1i thi\u1ec3u th\u1ea5p, x\u00e1c minh nhanh, nhi\u1ec1u ph\u01b0\u01a1ng th\u1ee9c r\u00fat ti\u1ec1n v\u00e0 n\u1ec1n t\u1ea3ng th\u00e2n thi\u1ec7n v\u1edbi ng\u01b0\u1eddi m\u1edbi, r\u1ea5t ph\u00f9 h\u1ee3p cho nh\u00e0 \u0111\u1ea7u t\u01b0 m\u1edbi b\u1eaft \u0111\u1ea7u v\u1edbi c\u1ed5 phi\u1ebfu c\u00f4ng ngh\u1ec7 sinh h\u1ecdc."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"L\u00e0m th\u1ebf n\u00e0o \u0111\u1ec3 b\u1eaft \u0111\u1ea7u \u0111\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Kiniksa Pharmaceuticals (KNSA)?","answer":"B\u1ea1n n\u00ean ch\u1ecdn m\u1ed9t n\u1ec1n t\u1ea3ng giao d\u1ecbch c\u00f3 truy c\u1eadp NASDAQ, ho\u00e0n t\u1ea5t x\u00e1c minh t\u00e0i kho\u1ea3n, n\u1ea1p ti\u1ec1n, t\u00ecm m\u00e3 c\u1ed5 phi\u1ebfu KNSA, ch\u1ecdn lo\u1ea1i l\u1ec7nh ph\u00f9 h\u1ee3p v\u00e0 theo d\u00f5i v\u1ecb th\u1ebf c\u1ee7a m\u00ecnh, \u0111\u1eb7c bi\u1ec7t l\u00e0 c\u00e1c ng\u00e0y c\u00f4ng b\u1ed1 b\u00e1o c\u00e1o thu nh\u1eadp."},{"question":"Gi\u00e1 c\u1ed5 phi\u1ebfu KNSA hi\u1ec7n t\u1ea1i l\u00e0 bao nhi\u00eau?","answer":"T\u00ednh \u0111\u1ebfn ng\u00e0y 29 th\u00e1ng 8 n\u0103m 2025, gi\u00e1 c\u1ed5 phi\u1ebfu KNSA l\u00e0 $33,50 tr\u00ean s\u00e0n NASDAQ."},{"question":"Nh\u1eefng r\u1ee7i ro ch\u00ednh khi \u0111\u1ea7u t\u01b0 v\u00e0o Kiniksa l\u00e0 g\u00ec?","answer":"C\u00e1c r\u1ee7i ro bao g\u1ed3m r\u00e0o c\u1ea3n ph\u00ea duy\u1ec7t c\u1ee7a FDA, bi\u1ebfn \u0111\u1ed9ng cao trong ng\u00e0nh c\u00f4ng ngh\u1ec7 sinh h\u1ecdc, c\u1ea1nh tranh t\u1eeb c\u00e1c c\u00f4ng ty d\u01b0\u1ee3c l\u1edbn v\u00e0 s\u1ef1 kh\u00f4ng \u1ed5n \u0111\u1ecbnh trong l\u1ee3i nhu\u1eadn do chi ph\u00ed nghi\u00ean c\u1ee9u v\u00e0 ph\u00e1t tri\u1ec3n."},{"question":"D\u1ef1 b\u00e1o gi\u00e1 c\u1ed5 phi\u1ebfu KNSA trong t\u01b0\u01a1ng lai nh\u01b0 th\u1ebf n\u00e0o?","answer":"D\u1ef1 b\u00e1o gi\u00e1 \u0111\u1ebfn n\u0103m 2030 c\u00f3 th\u1ec3 \u0111\u1ea1t tr\u00ean $100 nh\u1edd s\u1ef1 t\u0103ng tr\u01b0\u1edfng c\u1ee7a ARCALYST, ti\u1ebfn tri\u1ec3n trong pipeline v\u00e0 m\u1edf r\u1ed9ng th\u1ecb tr\u01b0\u1eddng qu\u1ed1c t\u1ebf."},{"question":"T\u1ea1i sao n\u00ean s\u1eed d\u1ee5ng Pocket Option \u0111\u1ec3 \u0111\u1ea7u t\u01b0 v\u00e0o KNSA?","answer":"Pocket Option c\u00f3 s\u1ed1 ti\u1ec1n n\u1ea1p t\u1ed1i thi\u1ec3u th\u1ea5p, x\u00e1c minh nhanh, nhi\u1ec1u ph\u01b0\u01a1ng th\u1ee9c r\u00fat ti\u1ec1n v\u00e0 n\u1ec1n t\u1ea3ng th\u00e2n thi\u1ec7n v\u1edbi ng\u01b0\u1eddi m\u1edbi, r\u1ea5t ph\u00f9 h\u1ee3p cho nh\u00e0 \u0111\u1ea7u t\u01b0 m\u1edbi b\u1eaft \u0111\u1ea7u v\u1edbi c\u1ed5 phi\u1ebfu c\u00f4ng ngh\u1ec7 sinh h\u1ecdc."}]}},"yoast_head":"\nC\u00e1ch mua c\u1ed5 phi\u1ebfu Kiniksa Pharmaceuticals International, plc (KNSA) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Kiniksa Pharmaceuticals International, plc (KNSA)<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-kiniksa-pharmaceuticals-international\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"C\u00e1ch mua c\u1ed5 phi\u1ebfu Kiniksa Pharmaceuticals International, plc (KNSA) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Kiniksa Pharmaceuticals International, plc (KNSA)\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-kiniksa-pharmaceuticals-international\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-29T12:04:09+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-kiniksa-pharmaceuticals-international\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-kiniksa-pharmaceuticals-international\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"C\u00e1ch mua c\u1ed5 phi\u1ebfu Kiniksa Pharmaceuticals International, plc (KNSA) – \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Kiniksa Pharmaceuticals International, plc (KNSA)\",\"datePublished\":\"2025-08-29T12:04:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-kiniksa-pharmaceuticals-international\/\"},\"wordCount\":25,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-kiniksa-pharmaceuticals-international\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals8.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"vt-VT\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-kiniksa-pharmaceuticals-international\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-kiniksa-pharmaceuticals-international\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-kiniksa-pharmaceuticals-international\/\",\"name\":\"C\u00e1ch mua c\u1ed5 phi\u1ebfu Kiniksa Pharmaceuticals International, plc (KNSA) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Kiniksa Pharmaceuticals International, plc (KNSA)\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-kiniksa-pharmaceuticals-international\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-kiniksa-pharmaceuticals-international\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals8.webp\",\"datePublished\":\"2025-08-29T12:04:09+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-kiniksa-pharmaceuticals-international\/#breadcrumb\"},\"inLanguage\":\"vt-VT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-kiniksa-pharmaceuticals-international\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"vt-VT\",\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-kiniksa-pharmaceuticals-international\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals8.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals8.webp\",\"width\":1024,\"height\":576},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-kiniksa-pharmaceuticals-international\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/vt\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"C\u00e1ch mua c\u1ed5 phi\u1ebfu Kiniksa Pharmaceuticals International, plc (KNSA) – \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Kiniksa Pharmaceuticals International, plc (KNSA)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/vt\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/vt\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"vt-VT\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/vt\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"vt-VT\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/vt\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Kiniksa Pharmaceuticals International, plc (KNSA) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Kiniksa Pharmaceuticals International, plc (KNSA)","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-kiniksa-pharmaceuticals-international\/","og_locale":"en_US","og_type":"article","og_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Kiniksa Pharmaceuticals International, plc (KNSA) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Kiniksa Pharmaceuticals International, plc (KNSA)","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-kiniksa-pharmaceuticals-international\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-29T12:04:09+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-kiniksa-pharmaceuticals-international\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-kiniksa-pharmaceuticals-international\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/vt\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Kiniksa Pharmaceuticals International, plc (KNSA) – \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Kiniksa Pharmaceuticals International, plc (KNSA)","datePublished":"2025-08-29T12:04:09+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-kiniksa-pharmaceuticals-international\/"},"wordCount":25,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-kiniksa-pharmaceuticals-international\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals8.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"vt-VT","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-kiniksa-pharmaceuticals-international\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-kiniksa-pharmaceuticals-international\/","url":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-kiniksa-pharmaceuticals-international\/","name":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Kiniksa Pharmaceuticals International, plc (KNSA) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Kiniksa Pharmaceuticals International, plc (KNSA)","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/vt\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-kiniksa-pharmaceuticals-international\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-kiniksa-pharmaceuticals-international\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals8.webp","datePublished":"2025-08-29T12:04:09+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/vt\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-kiniksa-pharmaceuticals-international\/#breadcrumb"},"inLanguage":"vt-VT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-kiniksa-pharmaceuticals-international\/"]}]},{"@type":"ImageObject","inLanguage":"vt-VT","@id":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-kiniksa-pharmaceuticals-international\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals8.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals8.webp","width":1024,"height":576},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-kiniksa-pharmaceuticals-international\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/vt\/"},{"@type":"ListItem","position":2,"name":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Kiniksa Pharmaceuticals International, plc (KNSA) – \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Kiniksa Pharmaceuticals International, plc (KNSA)"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/vt\/#website","url":"https:\/\/pocketoption.com\/blog\/vt\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/vt\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"vt-VT"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/vt\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"vt-VT","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/vt\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"vt_VT","wpml_translations":{"pt_AA":{"locale":"pt_AA","id":358267,"slug":"how-to-buy-kiniksa-pharmaceuticals-international","post_title":"Como comprar a\u00e7\u00f5es da Kiniksa Pharmaceuticals International, plc (KNSA) - Investimento em a\u00e7\u00f5es da Kiniksa Pharmaceuticals International, plc (KNSA)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-kiniksa-pharmaceuticals-international\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/posts\/358270","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/comments?post=358270"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/posts\/358270\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/media\/334054"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/media?parent=358270"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/categories?post=358270"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/vt\/wp-json\/wp\/v2\/tags?post=358270"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}